bs-15569R **[Primary Antibody]**

IGFBPL1 Rabbit pAb

www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800

DATASHEET

Host: Rabbit **Isotype:** IgG

Clonality: Polyclonal

GeneID: 347252 **SWISS:** Q8WX77

Target: IGFBPL1

Immunogen: KLH conjugated synthetic peptide derived from human IGFBPL1: 201-278/278.

Purification: affinity purified by Protein A

Concentration: 1mg/ml

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: IGFBPL1 is a secreted IGF (Insulin-like growth factor) binding protein that is known to contain an Ig-like C2-type (immunoglobulin-like) domain, an IGFBP N-terminal domain and a Kazal-like domain. IGF-binding proteins characteristically act to extend the half-life of IGFs and may influence the growth promoting effects of the IGFs. The interaction of IGFBPs with IGFs can affect cell surface receptors, specifically, IGFBPs may enhance or decrease a cells insulin sensitivity. IGFBPL1 has been found to be down-regulated in multiple tumors and thus may be a likely tumor suppressor candidate. Highly expressed in both brain and testis, IGFBPL1 is found at lower levels in the prostate, bladder and lung.

Applications: **IHC-P** (1:100-500)
IHC-F (1:100-500)
IF (1:100-500)
ELISA (1:5000-10000)

Reactivity: (predicted: Human, Mouse, Rat, Pig, Sheep, Cow, Dog, Horse)

Predicted MW.: 26 kDa

Subcellular Location: Secreted

SELECTED CITATIONS

- **[IF=5.496]** Yang Y et al. Epigenetic silencing of IGFBPL1 promotes esophageal cancer growth by activating PI3K-AKT signaling. Clin Epigenetics. 2020 Feb 10;12(1):22. IHC ;Human. 32041673